Ascentage Pharma Announces 2023 Interim Results Highlighting Significant Increase in Sales and Clearance for Global Registrational Phase III Trial
/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...